Actavis plc (NYSE:ACT) Keeps Its Phase Iii Promise With Molecular Partners’ Eye Drug

Actavis plc (NYSE:ACT) is on track with maintaining its promise to Allergan, Inc. (NYSE:AGN) through the upcoming introduction of phase III trials for abicipar. The drug is licensed by Sweden-based Molecular Partners. The drug is the first of the projects that have a direct influence on the $66 million merger. Ambicipar is a promising drug […]

Johnson & Johnson (NYSE:JNJ) And Actavis plc (NYSE:ACT) Cleared Of Painkillers Addiction Allegations

Johnson & Johnson (NYSE:JNJ) and Actavis plc (NYSE:ACT) have been cleared of any wrongdoing after being accused of not doing enough to warn patients of addiction risks posed by their prescription pain killers on sale. However, Purdue Pharma will have to make its case after a U.S District Court concluded it had a case to […]

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) Gears To Comply With Regulatory Requirements To Acquire Mylan NV (NASDAQ:MYL)

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) on Wednesday announced plans to sell some of its operations that are necessary to meet regulatory formalities to purchase its competitor Mylan NV (NASDAQ:MYL). Teva Pharmaceutical has not revealed the details of operations that are put on sale for the possible acquisition. In a bid to reduce pressure for […]

The Market Outlook: Durata Therapeutics (DRTX), Unilife Corp (UNIS), Revolution Lighting Technologies (RVLT)

Boston, MA 10/06/2014 (wallstreetpr) – Durata Therapeutics Inc (NASDAQ:DRTX) has agreed to be purchased by Actavis plc (NYSE:ACT). The deal is expected to complete later this year or early next year. DRTX has been offered $23 per share, which suggests 66% premium from the previous closing price before the deal was made public. The companies said […]

Pfizer Inc. (NYSE:PFE) Can Raise Its Bid For AstraZeneca plc (ADR) (NYSE:AZN)

Boston, MA 08/25/2014 (wallstreetpr) – It seems Pfizer Inc. (NYSE:PFE) is adamant for an overseas takeover to get the tax inversion benefits and expand its product portfolio. It can place a renew bid for AstraZeneca plc (ADR) (NYSE:AZN), on November 26, 2014. But if AstraZeneca wants, it can invite Pfizer for further discussion after August […]

Actavis plc (NYSE:ACT) Beats Market Expectations, Provide Positive 2015 Outlook: Reports

Boston, MA 08/06/2014 (wallstreetpr) – Zacks Consensus looked quite confident at the time it expected $3.37 per share earnings for Actavis plc (NYSE:ACT), but it was proved wrong. ACT posted eye-popping earnings figure of $3.42 per share which was 70% higher than the last year’s figure. Details of financial performance: According to reports, the total […]

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) – Nuvigil Patent Infringement Lawsuit Resolved

Boston, MA 06/20/2014 (wallstreetpr) – Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) continues to file a series of patent infringement lawsuits against various company as it seeks to protect its products from generic competition. It goes without saying that some of these cases result in unnecessary expenses, prompting companies to opt for early settlement as it […]

Allergan, Inc. (NYSE:AGN) Loses Latisse Eyelash Ruling; Rejects Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Offer

Boston, MA 06/11/2014 (wallstreetpr) – Allergan, Inc. (NYSE:AGN), the Botox wrinkle therapy maker, lost a ruling in the appeals court which will cause generic versions of the company’s Latisse eyelash medicine enter the marketplace. Ruling Rejected Allergan, Inc. (NYSE:AGN) and Duke University owned two patents on its drug Latisse but as per the website posting, […]

Stock Market Digest: Generics drug major Actavis plc (NYSE:ACT), Iridium Communications Inc. (NASDAQ:IRDM), Ruckus Wireless Inc (NYSE:RKUS)

Boston, MA 06/02/2014 (wallstreetpr) – Generics drug major Actavis plc (NYSE:ACT) is out to spoil the party for the Swiss-based AstraZeneca plc (ADR) (NYSE:AZN). ACT filed an Abbreviated New Drug Application with the U.S Food and Drug Administration (FDA) in attempts to seek market approval for a generic version of AstraZeneca’s type 2 diabetes drug known […]

Actavis plc Ordinary Shares (NYSE:ACT) 4Q 2013 Sales Increase by 59%

Boston, MA 02/20/2014 (wallstreetpr) – Actavis plc Ordinary Shares (NYSE:ACT), posted its fourth quarter results for the period ending 31, 2013 that show a 59% increase in revenue of $2.78 billion for the quarter, compared to 4Q 2012 revenues of $1.75 billion. This was the most successful year for Actavis that saw it acquire Warner […]

Valeant Pharmaceuticals Intl Inc (NYSE:VRX), Actavis Inc (NYSE:ACT) merger drops action

Boston, MA 04/29/2013 (wallstreetpr) – The merger talks that were in progress between Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (Closed: $73.16, Down by 0.58%) and Actavis Inc (NYSE:ACT) (Closed: $100.94, Up by 2.07%) have come to a grinding halt. People familiar with the matter said that that this is primarily due to a disagreement on the […]